文献速递淋巴瘤

来那度胺联合利妥昔单抗一线治疗边缘区淋巴瘤:亚组分析与长期随访

Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.
PubMed 文献 · Br J Haematol · 2019-03-28

这项开放标签2期研究纳入既往未治疗的III/IV期边缘区淋巴瘤患者,接受来那度胺联合利妥昔单抗治疗。总缓解率为93%,完全缓解/未确认完全缓解率为70%;中位随访75.1个月时中位无进展生存期为59.8个月,5年总生存率为96%。

要点

  • 总缓解率为93%,完全缓解/未确认完全缓解率为70%。
  • 中位随访75.1个月,中位无进展生存期为59.8个月,5年总生存率为96%。
  • 3级血液学不良事件为中性粒细胞减少33%和白细胞减少7%。

核心结论

  • 延长随访后,接受来那度胺联合利妥昔单抗治疗的边缘区淋巴瘤患者结局稳健,未出现非预期晚期或迟发毒性。

研究设计与样本

  • 这是一项研究者发起的2期开放标签研究,纳入既往未治疗的III/IV期边缘区淋巴瘤患者。
  • 治疗方案为来那度胺20 mg/天,第1-21天;利妥昔单抗375 mg/m2,每28天周期第1天;缓解者继续治疗≥6-12个周期。
  • 主要终点为总缓解率;次要终点为完全缓解和部分缓解、安全性及无进展生存期。

主要发现

  • 总缓解率为93%,其中70%达到完全缓解/未确认完全缓解。
  • 中位随访75.1个月时,中位无进展生存期为59.8个月,5年总生存率为96%。
  • 大多数非血液学不良事件为1/2级。
  • 3级血液学不良事件为中性粒细胞减少(33%)和白细胞减少(7%);4级为白细胞减少(3%)和血小板减少(3%)。
  • 两例患者死于继发性恶性肿瘤;无治疗相关死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lack of consensus for first-line marginal zone lymphoma (MZL) treatment and toxicities associated with currently available systemic therapies have inspired evaluation of immunotherapeutic agents yielding robust outcomes with improved tolerability. We previously reported durable efficacy with first-line lenalidomide and rituximab (R2 ) in follicular lymphoma, MZL and small lymphocytic lymphoma with a subsequent long-term follow-up shown here in MZL patients. This phase 2 investigator-initiated study included previously untreated, stage III/IV MZL patients treated with lenalidomide 20 mg/day on days 1-21 and rituximab 375 mg/m2 on day 1 of each 28-day cycle, continuing in responders for ≥6-12 cycles. The primary endpoint was overall response rate (ORR); secondary endpoints were complete and partial response (CR, PR), safety, and progression-free survival (PFS). The ORR was 93% with 70% attaining CR/CR unconfirmed. At median follow-up of 75·1 months, median PFS was 59·8 months and 5-year OS was 96%. Most non-haematological adverse events (AE) were grade 1/2. Grade 3 haematological AEs were neutropenia (33%) and leucopenia (7%), and grade 4 were leucopenia (3%) and thrombocytopenia (3%). Two patients died of secondary malignancies; no treatment-related fatalities occurred. With extended follow-up, outcomes for MZL patients receiving R2 were robust with no unexpected late or delayed toxicities.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Becnel MR, Nastoupil LJ, Samaniego F, et al. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019. PMID: 30919940. doi:10.1111/bjh.15843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。